Ibrutinib has 'unprecedented' impact on mantle cell lymphoma

An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma continues to show unprecedented and durable results with few side effects.

http://www.eurekalert.org/pub_releases/2012-12/uotm-ih121412.php